STRO · Insider Trading
Sutro Biopharma, Inc.
Every open-market purchase and sale reported by STRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-22 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | MIXED | +2,405 | −$20.63K |
| 2026-06-09 | Sukhi Jagpal | Director | A | +10,000 deriv. | — |
| 2026-06-09 | Michael Dybbs | Director | A | +10,000 deriv. | — |
| 2026-06-09 | Connie Matsui | Director | A | +10,000 deriv. | — |
| 2026-06-09 | Daniel H Petree | Director | A | +10,000 deriv. | — |
| 2026-06-09 | James P Panek | Director | A | +10,000 deriv. | — |
| 2026-06-09 | Jon Marc Wigginton | Director | A | +10,000 deriv. | — |
| 2026-06-09 | Heidi Hunter | Director | A | +10,000 deriv. | — |
| 2026-06-09 | Joseph M Lobacki | Director | A | +10,000 deriv. | — |
| 2026-06-02 | Gregory K. Chow | CFO | M | +2,500 | — |
| 2026-03-06 | David Pauling | Chief Admin. Ofcr. & GC | MIXED | +398 | −$5.90K |
| 2026-03-06 | Jane Chung | Chief Executive Officer | MIXED | +506 | −$6.01K |
| 2026-03-03 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | MIXED | +2,335 | −$33.52K |
| 2026-03-03 | Gregory K. Chow | CFO | A | +45,000 deriv. | — |
| 2026-03-03 | David Pauling | Chief Admin. Ofcr. & GC | MIXED | +2,177 | −$31.21K |
| 2026-03-03 | Jane Chung | Chief Executive Officer | MIXED | +6,888 | −$83.13K |
| 2025-12-29 | Gregory K. Chow | CFO | A | +8,200 deriv. | — |
| 2025-12-29 | Daniel H Petree | Director | A | +1,500 deriv. | — |
| 2025-12-29 | Heidi Hunter | Director | A | +1,500 deriv. | — |
| 2025-12-29 | James P Panek | Director | A | +1,500 deriv. | — |
| 2025-12-29 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | A | +7,925 deriv. | — |
| 2025-12-29 | Michael Dybbs | Director | A | +1,500 deriv. | — |
| 2025-12-29 | Joseph M Lobacki | Director | A | +1,500 deriv. | — |
| 2025-12-29 | Sukhi Jagpal | Director | A | +1,500 deriv. | — |
| 2025-12-29 | Connie Matsui | Director | A | +1,500 deriv. | — |
| 2025-12-29 | David Pauling | Chief Admin. Ofcr. & GC | A | +7,200 deriv. | — |
| 2025-12-29 | Jon Marc Wigginton | Director | A | +1,500 deriv. | — |
| 2025-12-16 | Jane Chung | Chief Executive Officer | MIXED | +1,606 | −$7.17K |
| 2025-10-16 | Gregory K. Chow | CFO | Buy | +19,750 | +$16.00K |
| 2025-10-16 | Connie Matsui | Director | Buy | +50,000 | +$39.95K |
| 2025-10-16 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | Buy | +17,000 | +$13.61K |
| 2025-10-16 | David Pauling | Chief Admin. Ofcr. & GC | Buy | +12,504 | +$9.99K |
| 2025-10-16 | Jane Chung | Chief Executive Officer | Buy | +12,500 | +$10.01K |
| 2025-09-22 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | MIXED | +24,083 | −$12.08K |
| 2025-08-26 | Jane Chung | Chief Executive Officer | MIXED | +12,042 | −$5.37K |
| 2025-08-26 | Barbara Leyman | Chief Business Officer | MIXED | +16,056 | −$6.98K |
| 2025-06-10 | Sukhi Jagpal | Director | A | +50,000 deriv. | — |
| 2025-06-10 | Joseph M Lobacki | Director | A | +50,000 deriv. | — |
| 2025-06-10 | Daniel H Petree | Director | A | +50,000 deriv. | — |
| 2025-06-10 | James P Panek | Director | A | +50,000 deriv. | — |
| 2025-06-10 | Connie Matsui | Director | A | +50,000 deriv. | — |
| 2025-06-10 | Heidi Hunter | Director | A | +50,000 deriv. | — |
| 2025-06-10 | Michael Dybbs | Director | A | +50,000 deriv. | — |
| 2025-06-10 | Jon Marc Wigginton | Director | A | +50,000 deriv. | — |
| 2025-06-02 | Gregory K. Chow | CFO | A | +375,000 deriv. | — |
| 2025-05-19 | Edward C Albini | CFO AND SECRETARY | MIXED | +28,724 | −$14.08K |
| 2025-05-05 | Venkatesh Srinivasan | CHIEF TECH OP OFFICER | MIXED | +1,606 | −$957 |
| 2025-05-05 | Linda A Fitzpatrick | CHIEF PEOPLE & COMM. OFFICER | MIXED | +24,311 | −$14.49K |
| 2025-05-05 | Anne Elizabeth Borgman | CHIEF MEDICAL OFFICER | MIXED | +44,354 | −$26.44K |
| 2025-04-15 | Venkatesh Srinivasan | CHIEF TECH OP OFFICER | MIXED | +13,647 | −$4.56K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William J Newell | CEO | 40,905 | $447.50K |
| Jane Chung | Chief Executive Officer | 21,285 | $232.86K |
| Edward C Albini | CFO AND SECRETARY | 15,652 | $171.23K |
| Linda A Fitzpatrick | CHIEF PEOPLE & COMM. OFFICER | 13,782 | $150.78K |
| Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | 12,367 | $135.29K |
| Anne Elizabeth Borgman | CHIEF MEDICAL OFFICER | 10,622 | $116.20K |
| David Pauling | Chief Admin. Ofcr. & GC | 9,748 | $106.64K |
| Venkatesh Srinivasan | CHIEF TECH OP OFFICER | 5,369 | $58.74K |
| Connie Matsui | Director | 5,000 | $54.70K |
| Gregory K. Chow | CFO | 4,725 | $51.69K |
| Daniel H Petree | Director | 2,246 | $24.57K |
| Barbara Leyman | Chief Business Officer | 1,606 | $17.57K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STRO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.